Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease
| Autor: | Hans L. Hillege, Paul E. de Jong, Ron T. Gansevoort, Dick de Zeeuw, Auke H. Brantsma, Stephan J. L. Bakker |
|---|---|
| Přispěvatelé: | Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), Lifestyle Medicine (LM), Groningen Kidney Center (GKC) |
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Urology Renal function urologic and male genital diseases Cohort Studies chemistry.chemical_compound INSUFFICIENCY Risk Factors STRATIFICATION medicine Albuminuria Humans Prospective Studies Renal Insufficiency Chronic Prospective cohort study Aged ALL-CAUSE MORTALITY GENERAL-POPULATION Transplantation Creatinine Kidney business.industry HIGH BLOOD-PRESSURE MICROALBUMINURIA Middle Aged medicine.disease Prognosis Survival Analysis PREVENTION female genital diseases and pregnancy complications Surgery INDIVIDUALS medicine.anatomical_structure chemistry Nephrology Cardiovascular Diseases RISK-FACTORS Microalbuminuria Female Hemodialysis medicine.symptom business FOLLOW-UP Kidney disease Glomerular Filtration Rate |
| Zdroj: | Nephrology Dialysis Transplantation, 23(12), 3851-3858. Oxford University Press |
| ISSN: | 1460-2385 0931-0509 |
| Popis: | Background. The Kidney Disease Outcomes Quality Initiative guidelines aim to define chronic kidney disease (CKD) and classify its stages. Stage 3 CKD generally receives more attention than stage 1 or 2, because the more impaired glomerular filtration rate (GFR) in stage 3 suggests a higher cardiovascular and renal risk. In this study we evaluated cardiovascular and renal outcome in subjects with stage 1 and 2 CKD. For comparison, we also studied these outcomes in stage 3 CKD.Methods. We used data of 8495 subjects of the PREVEND study, a prospective community-based cohort study, with data on urinary albumin excretion (UAE) and serum creatinine available. As measure of cardiovascular outcome, combined cardiovascular morbidity and mortality was used. As renal outcome, mean annual change of estimated GFR (eGFR) was used.Results. 6905 subjects had no CKD; 243, 856 and 491 subjects had stage 1, 2 and 3 CKD, respectively. During a median follow-up of 7.5 years 565 cardiovascular events occurred. Incidence rates of cardiovascular events were higher (P 30 mg/24 h, age- and sex-adjusted HRs for CVD were 1.0 (0.7-1.4) and 1.6 (1.1-2.3) and the change in eGFR was 0.2 versus -0.3 ml/min/1.73 m(2)/year, respectively.Conclusion. Subjects with stage 1 or 2 CKD have an increased risk for adverse cardiovascular and renal outcome and should receive equal attention as subjects with stage 3 CKD. Subdividing stage 3 CKD according to the presence or absence of a UAE > 30 mg/24 h improves risk stratification within this stage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|